Pedestrians walking across a street in Sydney. Credit: AdobeStock

Progress towards hepatitis C elimination: Insights from modelling

Join us for a hybrid event where Professor Natasha Martin will share insights using modelling on what is needed to achieve hepatitis C elimination.

Event date
Tuesday 25 July 2023
Event time
1:00pm – 2:00pm
Event address
In-person & online. Kirby Institute, Seminar Room Level 6, Wallace Wurth Building, Kensington Campus, UNSW Sydney


28 July marks World Hepatitis Day each year, bringing the world together to raise awareness of the global burden of viral hepatitis and to influence real change. Join us for a hybrid event where Professor Natasha Martin (joining online) will share insights using modelling on what is needed to achieve elimination.

Prof Martin will discuss how modelling has informed monitoring strategies for hepatitis C virus (HCV) elimination, recent modelling work assessing whether the United States and Australia are on track to reach HCV elimination targets, and general implications of what is needed to reduce HCV incidence globally.

*A light lunch will be available for in-person attendance at 12:30pm.


Natasha Martin

Professor Natasha Martin

Natasha Martin is an infectious disease economic modeler who develops dynamic transmission models to evaluate the impact and cost-effectiveness of public health interventions. She is a Professor in the Division of Infectious Diseases and Global Public Health at the University of California San Diego and holds an honorary senior lecturer position at the University of Bristol. Her modelling work has informed the WHO Global Health Sector Strategy on Viral Hepatitis and several country and local elimination plans. 

Scientia Professor Gregory Dore

Scientia Professor Gregory Dore (Chair)

Gregory Dore is Head, Viral Hepatitis Clinical Research Program, Kirby Institute, UNSW Sydney, and Infectious Diseases Physician, St Vincent’s Hospital, Sydney, Australia. He has been involved in viral hepatitis and HIV epidemiological and clinical research, clinical care and public health policy for 20 years. He has developed extensive national and international collaborations, and is internationally recognised in the areas of hepatitis C virus (HCV) natural history and epidemiology, therapeutic strategies for acute and chronic HCV infection, particularly among people who inject drugs, and HCV elimination strategies.



Opinions expressed by individuals at this event are solely of those of the individual/s and do not necessarily represent the views or opinions of the Kirby Institute or UNSW.

Header image: AdobeStock